Home
NewsNewsCalifornia SB 729 now requires insured large employers to provide comprehensive coverage for infertility and IVF starting from 2026, significantly increasing workplace benefits.
California SB 729 marks a major expansion of fertility insurance coverage, requiring fully insured large group health plans to cover infertility diagnosis and treatment, including in vitro fertilization (IVF). Signed into law by Governor Gavin Newsom on September 29, 2024, the mandate takes effect January 1, 2026, reshaping employer-sponsored reproductive healthcare across the state. Under California SB 729, fully insured health plans covering 101 or more employees must provide comprehensive infertility benefits, closing long-standing coverage gaps and modernizing access to fertility care.
A key provision of California SB 729 is the expansion of the legal definition of infertility. The law now includes individuals who are unable to reproduce without medical intervention, whether alone or with a partner. Coverage eligibility extends to same-sex couples, single parents by choice, individuals with medical infertility, and those experiencing recurrent pregnancy loss. A diagnosis by a licensed physician based on medical, sexual, or reproductive history establishes eligibility.
For applicable large group policies, California SB 729 requires coverage for both the diagnosis and treatment of infertility. Mandated benefits include:
The law enforces cost-sharing parity, requiring infertility services to be subject to the same deductibles, copayments, and coinsurance as other covered medical benefits. Insurers may not impose more restrictive limits or exclusions on infertility care, nor discriminate based on gender, marital or relationship status, sexual orientation, or family structure.
While California SB 729 does not mandate infertility coverage across all small group plans, carriers offering policies to employers with 100 or fewer employees must provide at least one plan option that includes comprehensive infertility benefits. Employers electing such coverage must comply with the same benefit and cost-sharing standards applied to large group plans.
The mandate does not apply to self-funded or level-funded health plans, which remain governed by federal ERISA regulations. Additional exemptions include religious employers, specialized health plans, Medi-Cal, and certain state and CalPERS contracts, with some exemptions extending until July 1, 2027.
Importantly, California SB 729 applies to fully insured plans covering California employees, regardless of whether the policy is issued inside or outside the state.
Employers with fully insured large group health plans should review their benefits and confirm compliance with California SB 729. Organizations offering separate fertility benefit programs may need to assess potential overlap with the new mandate. Although self-funded employers are exempt, the law is expected to influence evolving market standards and employee expectations around fertility coverage.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
